Results 11 to 20 of about 232,812 (303)
Multiple myeloma in people of working age in Czechia, Germany, and Poland: findings from a qualitative interview study [PDF]
, 2023 Purpose The study sought to understand the experiences of working age adults with myeloma and their partner/family members, living in Czechia, Germany, and Poland.
Forbat, Liz
core +1 more source
New England Journal of Medicine, 2004 AbstractMultiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present a historically focused review of the disease, from the description of the first case in 1844 to the present.
Robert A, Kyle, S Vincent, Rajkumar
openaire +8 more sources
Annual Review of Medicine, 2011 Multiple myeloma (MM) is a B cell neoplasm of the bone marrow with a complex array of clinical manifestations including anemia, bone lesions, hypercalcemia, renal dysfunction, and compromised immune function. It accounts for 10%–15% of all hematologic malignancies, and 20% of deaths related to cancers of the blood and bone marrow.
Jacob, Laubach +2 more
openaire +4 more sources
Myeloma of the Oesophagus [PDF]
Journal of Clinical Pathology, 1972 A case of myeloma of the oesophagus is presented. A search of the literature has revealed no other. The tumour was treated by local resection and postoperative treatment with cyclophosphamide was attempted. The patient died 14 months after operation from a massive myocardial infarct and at necropsy no tumour was found in any organ.
W T, Morris, J L, Pead
openaire +2 more sources
Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma [PDF]
, 2013 Copyright @ 2013 Macmillan Publishers Limited. This is the author's accepted manuscript. The final published article is available from the link below.Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM).
Papa, S +9 more
core +1 more source
Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma [PDF]
, 2003 High-dose chemotherapy with autologous peripheral blood stem cell transplantation is the standard treatment of patients with multiple myeloma today. In this study we used a combination mobilizing chemotherapy containing ifosfamide with G-CSF before stem ...
Werding, N. +5 more
core +2 more sources
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) [PDF]
, 2021 © The Author(s) 2020.Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM ...
Merlini, Giampolo +28 more
core +1 more source
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
Experimental Hematology & Oncology, 2022 Cancer cells are well-known for their capacity to adapt their metabolism to their increasing energy demands which is necessary for tumor progression. This is no different for Multiple Myeloma (MM), a hematological cancer which develops in the bone marrow
Inge Oudaert +6 more
doaj +1 more source
Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer
Journal of Experimental & Clinical Cancer Research, 2021 Despite improvements in outcome, 15-25% of newly diagnosed multiple myeloma (MM) patients have treatment resistant high-risk (HR) disease with a poor survival.
Hussein Ghamlouch +11 more
doaj +1 more source
Cell Death and Disease, 2023 Bruton’s tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but intrinsic or acquired resistance inevitably develops.
Yijing Li +15 more
doaj +1 more source